ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes
Endocrinology · 2024
DOI: 10.1210/endocr/bqae111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, 2024. Verfasst von Megan E Yates und 11 weiteren Autor:innen. Beteiligte Einrichtung: Women's Cancer Research Center, Magee-Women Research Institute, Pittsburgh, PA 15213, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, The Breasties.
Abstract (Originalsprache)
Breast cancer is a leading cause of female mortality and despite advancements in personalized therapeutics, metastatic disease largely remains incurable due to drug resistance. The estrogen receptor (ER, ESR1) is expressed in two-thirds of all breast cancer, and under endocrine stress, somatic ESR1 mutations arise in approximately 30% of cases that result in endocrine resistance. We and others reported ESR1 fusions as a mechanism of ER-mediated endocrine resistance. ER fusions, which retain the activation function 1- and DNA-binding domains, harbor ESR1 exons 1 to 6 fused to an in-frame gene partner resulting in loss of the ER ligand-binding domain (LBD). We demonstrate that in a no-special type (invasive ductal carcinoma [IDC]-NST) and an invasive lobular carcinoma (ILC) cell line, ER fusions exhibit robust hyperactivation of canonical ER signaling pathways independent of estradiol or antiendocrine therapies. We employ cell line models stably overexpressing ER fusions with concurrent endogenous ER knockdown to minimize endogenous ER influence. Cell lines exhibited shared transcriptomic enrichment in pathways known to be drivers of metastatic disease, notably MYC signaling. Cells expressing the 3′ fusion partners SOX9 and YAP1 consistently demonstrated enhanced growth and cell survival. ILC cells expressing the DAB2 fusion led to enhanced growth, survival, and migration, phenotypes not appreciated in the IDC-NST DAB2 model. Herein, we report that cell line activity is subtype-, fusion-, and assay-specific, suggesting that LBD loss, the fusion partner, and the cellular landscape all influence fusion activities. Therefore, it will be critical to assess fusion frequency in the context of the clinicopathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Women's Cancer Research Center, Magee-Women Research Institute, Pittsburgh, PA 15213, USA.
- UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
- Medical Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
- Integrative Systems Biology Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
- Biomedical Masters Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
- Physician Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
ORCID-Profile: Megan E Yates, Zheqi Li, Xiaosong Wang, Jennifer M Atkinson, Jagmohan Hooda, Adrian V Lee, Steffi Oesterreich
Förderung
- NCI NIH HHS
- NIH HHS
- The Breasties
- UPMC Hillman Cancer Biology Program
- Hillman Foundation
- Breast Cancer Alliance
- Shear Family Foundation
- Pennsylvania Department of Health
Zitieren
APA
Yates, M. E., Waltermire, H., Mori, K., Li, Z., Li, Y., Guzolik, H., Wang, X., Liu, T., Atkinson, J. M., Hooda, J., Lee, A. V., & Oesterreich, S. (2024). ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes. Endocrinology. https://doi.org/10.1210/endocr/bqae111
Vancouver
Yates ME, Waltermire H, Mori K, Li Z, Li Y, Guzolik H, et al. ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes. Endocrinology. 2024. doi:10.1210/endocr/bqae111
BibTeX
@article{Yates2024,
author = {Yates, Megan E and Waltermire, Hunter and Mori, Kanako and Li, Zheqi and Li, Yiting and Guzolik, Hannah and Wang, Xiaosong and Liu, Tiantong and Atkinson, Jennifer M and Hooda, Jagmohan and Lee, Adrian V and Oesterreich, Steffi},
title = {ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes},
journal = {Endocrinology},
year = {2024},
doi = {10.1210/endocr/bqae111}
}
EUVIMED